Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery (NCT06826742) | Clinical Trial Compass
CompletedPhase 4
Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery
United States30 participantsStarted 2025-02-12
Plain-language summary
The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* English-speaking
* Age over 18 years old
* Scheduled cesarean delivery
Exclusion Criteria:
* Any contraindication to the administration of a spinal technique for anesthesia
* History of intolerance or adverse reaction to opioid medications
* History of chronic pain, opioid use \>30 OME/day, or substance use disorder
* History of obstructive sleep apnea, chronic obstructive pulmonary disease, or respiratory compromise (SpO2 \<92% on room air, or has a pre-existing oxygen requirement)
* History of liver or kidney failure
* Diagnosis of pre-eclampsia with current pregnancy
* Depression requiring more than one medication
* Planned use of CSE technique
* BMI \>50.0 kg/m2
* ASA status IV, V
* No prior history of an ECG demonstrating QTc \> 440ms
* Surgical complication requiring conversion to general anesthesia